Animal Health, Nutrition and Technology Innovation Europe 2022

Shaping the Future of the Animal Health Industry by Showcasing Innovations in Prediction, Prevention and Treatment

What's new for 2022?
London, UK
21-23 February, 2022

A Covid Update from Animal Health, Nutrition and Technology Innovation Europe

We have been keeping a close eye on the developments of Covid-19 over the last month and the projections and announcements from the government. You may have seen that as of last week, the UK has now lifted travel and entry restrictions making the UK very much open for business and with no change to the guidelines from the Prime Minister, we are confident and excited about delivering the most anticipated reunion of the Animal Health industry on 21 – 23 February in London. For more information on travelling to England, click here. 

We are so thankful for the continued support that we have received from the industry. We are very committed to shaping the future of animal health by showcasing the latest innovations and to do this in a fruitful but safe and secure setting.

All in-person Kisaco Research events will prioritize the health and safety of our customers and colleagues and will run with strong safety measures in place following official government and local authority guidance, as well as any venue or location-specific regulations. Please read more info here: Covid-19: FAQs

Why Attend?

Now in its 7th year, Animal Health, Nutrition and Technology Innovation Europe is the sector’s premier Innovation Summit showcasing the most exciting investment opportunities globally and connecting businesses with investors and strategic corporate partners. Our mission is to engage all key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.

Following overwhelming feedback from the market, we have significantly expanded our programme this year with new focused content on nutrition and technology, alongside our production and companion animal health content. We will be running 4 separate innovation showcases in production animal health, companion animal health, nutrition, and technology.

Our new programme will address the full extent of this ever-evolving market. We are excited to provide an innovation platform that is bigger than ever and to continue to play a critical role in shaping the future of the animal health industry by presenting the most exciting innovations in prediction, prevention, and cure.

Book now to come and see for yourself!

550+
Attendees
1500+
1-to-1 Meetings
150+
Start-ups
35
Emerging Companies Presenting
25+
Private Meetings per person

Innovation Showcase

The Innovation Showcase is back for 2022!

The showcase is a unique opportunity for emerging companies with amazing technology to pre-sent in front of the industry’s most influential figures and investors. 40 start-ups, hand-picked by the Selection Committee, introduce themselves and their innovations and achievements on the main stage. This year, our presenting companies will be split into four distinguishable sections that will run across the show:

Production Animal Health

Companion Animal Health

Nutrition

Technology

2022 Showcase Finalists have now been announced! See all finalists by clicking here. 

2022 Speakers

 

Jeff Simmons

President & CEO
Elanco

Jeff Simmons

President & CEO
Elanco

Jeff Simmons

President & CEO
Elanco
 

Justine Conway

Global Head of Business Development
Elanco

Justine Conway

Global Head of Business Development
Elanco

Justine Conway

Global Head of Business Development
Elanco
 

Jasmeet Kaler

Professor
University of Nottingham

Jasmeet Kaler

Professor
University of Nottingham

Jasmeet Kaler

Professor
University of Nottingham
 

Dr Sam Hoste

Founder and CEO
Quantech Solutions

Dr Sam Hoste, through Quantech Solutions, has undertaken Agri-Tech leadership roles in business, central government and global consultancy firms. He has led sector-wide animal health improvement initiatives; was instrumental in the establishment of the UK’s Agri-Tech Centres and COO of the Centre for Innovation Excellence in Livestock.

Dr Sam Hoste

Founder and CEO
Quantech Solutions

Dr Sam Hoste

Founder and CEO
Quantech Solutions

Dr Sam Hoste, through Quantech Solutions, has undertaken Agri-Tech leadership roles in business, central government and global consultancy firms. He has led sector-wide animal health improvement initiatives; was instrumental in the establishment of the UK’s Agri-Tech Centres and COO of the Centre for Innovation Excellence in Livestock. He was a director and geneticist at ACMC and NPD, and UK Technical manager for PIC and a non-Exec at the Irish startup, Monford Ag.  He is currently working with a number of UK and international Agri-tech companies that provide data, vision and emissions reduction opportunities for farmers and supply chains.

 

Jean Scheftsik de Szolnok

Member of the Board of Directors responsible for Animal Health
Boehringer Ingelheim

Jean Scheftsik de Szolnok

Member of the Board of Directors responsible for Animal Health
Boehringer Ingelheim

Jean Scheftsik de Szolnok

Member of the Board of Directors responsible for Animal Health
Boehringer Ingelheim
 

Mark Scott

Co-Founder & CEO
Bella & Duke

Mark is Co-Founder and CEO of the pet wellness brand Bella & Duke which has become the largest DTC of natural pet food in just over 3 1/2 years in the UK.

Mark Scott

Co-Founder & CEO
Bella & Duke

Mark Scott

Co-Founder & CEO
Bella & Duke

Mark is Co-Founder and CEO of the pet wellness brand Bella & Duke which has become the largest DTC of natural pet food in just over 3 1/2 years in the UK.

 

Richard Hobson

CEO
Herdsy

Richard Hobson

CEO
Herdsy

Richard Hobson

CEO
Herdsy
 

Yemi Adesokan

CEO/CSO and Co-Founder
GNUbiotics

Yemi Adesokan is Chief Scientific Officer and Co-Founder at Gnubiotics SA,  a Lausanne, Switzerland biotech company pioneering the development of Human Milk Oligosacchrides (HMOs) for infants and adults as well as Animal Milk Oligosaccharides (AMOs) for companion animals.  Yemi has been recognized for his innovative and pioneering work with awards such as the Boston Business Journal 40 under 40 award and the  MIT Technology Review’s annual list of 35 top global innovators under the age of 35 TR35.

Yemi Adesokan

CEO/CSO and Co-Founder
GNUbiotics

Yemi Adesokan

CEO/CSO and Co-Founder
GNUbiotics

Yemi Adesokan is Chief Scientific Officer and Co-Founder at Gnubiotics SA,  a Lausanne, Switzerland biotech company pioneering the development of Human Milk Oligosacchrides (HMOs) for infants and adults as well as Animal Milk Oligosaccharides (AMOs) for companion animals.  Yemi has been recognized for his innovative and pioneering work with awards such as the Boston Business Journal 40 under 40 award and the  MIT Technology Review’s annual list of 35 top global innovators under the age of 35 TR35. Yemi has a PhD in Chemistry from the University of California, Irvine and completed a post-doctoral fellowship in Genetics with George Church at Harvard Medical School.

 

 

Robert Dawson

Founder
Vet-AI

Robert Dawson

Founder
Vet-AI

Robert Dawson

Founder
Vet-AI
 

Ryan William Honaker, PHD

Director of Microbiology
Nom Nom

Ryan William Honaker, PHD

Director of Microbiology
Nom Nom

Ryan William Honaker, PHD

Director of Microbiology
Nom Nom
 

David Speller

CEO
Optifarm

David Speller

CEO
Optifarm

David Speller

CEO
Optifarm
 

Dr. Jamie Crittall

Co-Founder & Commercial Director
Virtual Recall

Jamie qualified from Bristol Vet School in 1993. He owns two separate UK veterinary practices – one, a family-owned 147-year old multi-branch practice and the other, a 9-year old start-up (which he subsequently sold in December 2018), as well as global healthcare compliance technology company, Virtual Recall.

Dr. Jamie Crittall

Co-Founder & Commercial Director
Virtual Recall

Dr. Jamie Crittall

Co-Founder & Commercial Director
Virtual Recall

Jamie qualified from Bristol Vet School in 1993. He owns two separate UK veterinary practices – one, a family-owned 147-year old multi-branch practice and the other, a 9-year old start-up (which he subsequently sold in December 2018), as well as global healthcare compliance technology company, Virtual Recall.

Co-Founded with fellow veterinarian, Charlie Barton, as a result of their vision to enhance the intimate bond between all owners & their animals. They help vets create more valued customer experiences and drive improved business performance, to deliver better health and financial outcomes. They currently have their patent-pending, communication solution, iRecall® installed in over 1750 practices across three continents. It enables practices to send their clients their own bespoke messages, completely automatically, ensuring every animal and every client receive the appropriate communication - including immediate feedback - every time.

iRecall® sent over 26 million automated and personalized messages by SMS, email & post this year to over 3.5 million clients. helping them to become better informed and more engaged in the health and well-being of their 5.3 million animals, driven by their vets’ recommendations. Improving compliance, adherence and greater practice loyalty, delivering a virtuous value circle.  Additionally, iRecall® enhances practices’ digital reputations by capturing over 1 million Net Promoter Scores to date, with an average score of over 80, with promoters encouraged to provide written testimonials and online reviews.

During Lockdown, they developed a new direct-to-consumer solution, OurVet.Shop®. Providing practices with a simple, secure payment gateway to pay for in-clinic services & settling outstanding accounts as well as offering clients a new channel to purchase food and medicines (-including prescription) with home delivery.

 Virtual Recall was acquired by Zoetis in July 2020, and Jamie is now Senior Commercial Director within within Zoetis’ newly-formed Digital Practice Services Business Unit.

Jamie also has an all-encompassing knowledge and love for the media, being vet on set for film, tv & commercials for twenty plus years and a 5-year sabbatical in British television. He appeared regularly as a vet on The Big Breakfast; Sky News; BBC1’s The Really Useful Show, and latterly, co-presenting Pet Rescue’s spin off series, Pet Rescuers and Pet Rescue Roadshow. He has radio broadcast countrywide and is a regular speaker at UK veterinary business, technology and marketing seminars, conferences and events. Jamie is a Trustee of the Petplan Charitable Trust. Married with three children and a menagerie of pets and he can often be found mountain biking around the Surrey Hills.

 

Thomas Tillett

CEO & President
MBF Therapeutics

Thomas Tillett

CEO & President
MBF Therapeutics

Thomas Tillett

CEO & President
MBF Therapeutics
 

Dr Simon Doherty

Senior Lecturer (Education) in Animal Health & Welfare
Queens University Belfast (Institute of Global Food Security)

Dr Simon Doherty

Senior Lecturer (Education) in Animal Health & Welfare
Queens University Belfast (Institute of Global Food Security)

Dr Simon Doherty

Senior Lecturer (Education) in Animal Health & Welfare
Queens University Belfast (Institute of Global Food Security)
 

Andy Peters

Professor
University of Edinburgh & Arpexas

Andy Peters

Professor
University of Edinburgh & Arpexas

Andy Peters

Professor
University of Edinburgh & Arpexas
 

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd
 

Dawn Howard

Dawn Howard Chief Executive Officer
NOAH

Dawn Howard

Dawn Howard Chief Executive Officer
NOAH

Dawn Howard

Dawn Howard Chief Executive Officer
NOAH
 

Stephane Maddens

CEO
Vetbiobank

Stephane Maddens

CEO
Vetbiobank

Stephane Maddens

CEO
Vetbiobank
 

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.
 

Anton Xavier

Founder and CEO
K9 Biotech

Anton Xavier

Founder and CEO
K9 Biotech

Anton Xavier

Founder and CEO
K9 Biotech
 

Simon Grammel

CEO and Co-Founder
PetBioCell

Simon Grammel

CEO and Co-Founder
PetBioCell

Simon Grammel

CEO and Co-Founder
PetBioCell
 

Cees Jan Hollander

Global Farming Expertise Manager
Danone

Cees Jan Hollander

Global Farming Expertise Manager
Danone

Cees Jan Hollander

Global Farming Expertise Manager
Danone
 

Gavin Hodgson

Buying Managers: Meat, Fish & Poultry
Sainsbury's

Gavin Hodgson

Buying Managers: Meat, Fish & Poultry
Sainsbury's

Gavin Hodgson

Buying Managers: Meat, Fish & Poultry
Sainsbury's
 

Sven Arnouts

Business Development
Ghent University

Sven Arnouts

Business Development
Ghent University

Sven Arnouts

Business Development
Ghent University
 

Kristin Bloink

Vice President of Regulatory Affairs and Pharmacovigilance
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

Kristin Bloink

Vice President of Regulatory Affairs and Pharmacovigilance
Elanco

Kristin Bloink

Vice President of Regulatory Affairs and Pharmacovigilance
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

 

Duncan Lascelles

Co-Founder
Aniv8

B. Duncan X. Lascelles

BSc, BVSC, PhD, MRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS

Professor of Surgery and Pain Management
Director, Comparative Pain Research and Education Centre
Translational Research in Pain Programme,
North Carolina State University College of Veterinary Medicine, Raleigh, NC, 27606, USA

Duncan Lascelles

Co-Founder
Aniv8

Duncan Lascelles

Co-Founder
Aniv8

B. Duncan X. Lascelles

BSc, BVSC, PhD, MRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS

Professor of Surgery and Pain Management
Director, Comparative Pain Research and Education Centre
Translational Research in Pain Programme,
North Carolina State University College of Veterinary Medicine, Raleigh, NC, 27606, USA

After graduating from the veterinary program at the University of Bristol, U.K., with honors, in 1991 Dr. Lascelles completed a PhD in aspects of pre-emptive/perioperative analgesia at the University of Bristol. After an internship there, he completed his surgical residency at the University of Cambridge, U.K. He moved to Colorado for the Fellowship in Oncological Surgery at Colorado State University, then a period of post-doctoral research in feline pain and analgesia at the University of Florida, and is currently Professor in Small Animal Surgery and Pain Management at North Carolina State University. He is board-certified in small animal surgery by the Royal College of Veterinary Surgeons, the European College of Veterinary Surgeons, and the American College of Veterinary Surgeons.

He is director of the Comparative Pain Research and Education Centre (CPREC). His research program (Translational Research in Pain [TRiP]) is dedicated to answering critical questions about pain control and pain mechanisms through high quality, innovative research.  His career has been focused on developing algometry methods (methods to measure pain) in spontaneous disease animal models (pets with naturally occurring disease), and probing tissues from well-phenotyped animals with spontaneous disease to understand the neurobiology, with a strong translational focus. The aim of his research is to improve pain control in companion animals, and facilitate analgesic development in human medicine.  He has authored over 180 peer reviewed research papers and reviews and 190 research abstracts, as well as over 30 book chapters.

He has worked closely with industry partners in both animal and human health, helping to re-define the relationship between industry and academia. Through reviews and invited presentations he advocates for the use of spontaneous disease in animals to inform human therapeutic development. Recently, he organized a meeting of industry, academia, regulatory authorities (FDA) and the NIH to discuss measurement of chronic pain in companion animals and the application to human pain research (www.PAW2017.com), and is planning PAW2019. He is completing a year-long integrated sabbatical within a pain therapeutic company (Centrexion Therapeutics) that develops novel therapeutics for both humans and animals. He provides consulting services related to pain therapeutic development across all stages of animal therapeutic development, and for pre-clinical and Phase I stages of human therapeutic development.

Through his work in academia and industry, he contributes to and facilitates the development of novel pain therapeutics for companion animals, and advocates for the use of spontaneous disease in pets to inform human pain therapeutic development.

 

Maxime Madder

Director Biologics and Infectious Diseases
Clinglobal

Maxime Madder

Director Biologics and Infectious Diseases
Clinglobal

Maxime Madder

Director Biologics and Infectious Diseases
Clinglobal
 

Mattie Yeta

Head of Sustainability Group Strategy
DEFRA IT

Mattie Yeta

Head of Sustainability Group Strategy
DEFRA IT

Mattie Yeta

Head of Sustainability Group Strategy
DEFRA IT
 

Janet Helms

Global Sustainability Developer
IKEA

Janet Helms

Global Sustainability Developer
IKEA

Janet Helms

Global Sustainability Developer
IKEA
 

Robert Hof

Head of Digital & GSM Excellence
Boehringer Ingelheim

Robert Hof

Head of Digital & GSM Excellence
Boehringer Ingelheim

Robert Hof

Head of Digital & GSM Excellence
Boehringer Ingelheim
 

Rob Kelly

Independent Animal Health Expert

Rob Kelly

Independent Animal Health Expert

Rob Kelly

Independent Animal Health Expert
 

Kevin Kessler

Senior Veterinarian
Tyson Foods

Kevin Kessler

Senior Veterinarian
Tyson Foods

Kevin Kessler

Senior Veterinarian
Tyson Foods
 

Jason Johnson, Phd

Vice President & Global Chief Medical Officer
IDEXX

Jason Johnson, Phd

Vice President & Global Chief Medical Officer
IDEXX

Jason Johnson, Phd

Vice President & Global Chief Medical Officer
IDEXX
 

Linda Dixon

Group Leader, African Swine Fever Virus
The Pirbright Institute

Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.

Linda Dixon

Group Leader, African Swine Fever Virus
The Pirbright Institute

Linda Dixon

Group Leader, African Swine Fever Virus
The Pirbright Institute

Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.

Linda’s group has focussed on research underpinning the development of effective vaccines. Their approach has been to determine genome sequences of virulent and attenuated (weakened) isolates to help define the molecular determinants of virulence and identify those genes involved in evading host defences. The group has characterised ASFV proteins that inhibit host pathways involved in activating the host’s defences. These include proteins that inhibit host gene expression (transcription) responses, signal molecule induction and stress-activated responses. This knowledge has been applied to the rational development of candidate live attenuated ASFV vaccines by targeted gene deletions. 

In collaboration with the Vaccinology Group they have compared host responses in vitro (in glass) and in vivo (in animal) and induction of protective immune responses in pigs immunised with these gene manipulated and natural attenuated ASFV strains. The group has also collaborated with these groups and The Jenner Institute to screen ASFV antigens for those important in induction of protective immunity, in particular those which induce strong immune (CD8+ T cell) responses. This information will be applied to development of candidate virus-vectored vaccines.

In addition Linda provides advice on ASFV nationally to Defra and internationally as an OIE expert and is Chair of the Asfarviridae Study Group of the International Committee on Taxonomy of Viruses and a Jenner Institute Investigator. 

 

Justin Sherrard

Global Strategist - Animal Protein
Rabobank

As Global Strategist Animal Protein, Justin Sherrard is responsible for the timely and agenda-setting analysis of issues of strategic importance to animal protein companies around the world.

In his research and client engagement, Justin focusses on business opportunities in animal protein through, for example, increased production efficiencies, better access to growth markets and stronger supply chain models.

Justin Sherrard

Global Strategist - Animal Protein
Rabobank

Justin Sherrard

Global Strategist - Animal Protein
Rabobank

As Global Strategist Animal Protein, Justin Sherrard is responsible for the timely and agenda-setting analysis of issues of strategic importance to animal protein companies around the world.

In his research and client engagement, Justin focusses on business opportunities in animal protein through, for example, increased production efficiencies, better access to growth markets and stronger supply chain models.

Prior to his current role, Justin has worked at RaboResearch Food & Agribusiness as Global Manager Research, Global Strategist F&A Supply Chains, and General Manager of Food & Agribusiness Research for Rabobank in Australia and New Zealand. He joined Rabobank in 2009.

Justin has also worked as an independent advisor to leading blue chip companies, not-for-profit organisations and governments, applying his knowledge of food & agribusiness, energy and natural resources issues, including sustainability and climate change.

Justin has over 20 years of global experience having worked in Europe, the United States, Latin America, New Zealand as well as his native Australia. He holds a Master of Applied Science and Bachelor of Science from the University of New South Wales in Sydney, Australia.

 

 

Francois Maree

Research Director: Biologics and Infections Diseases
Clinglobal

Francois Maree

Research Director: Biologics and Infections Diseases
Clinglobal

Francois Maree

Research Director: Biologics and Infections Diseases
Clinglobal
 

Scott Holmstrom

Senior Director, Global Product Development
United Animal Health

Scott Holmstrom

Senior Director, Global Product Development
United Animal Health

Scott Holmstrom

Senior Director, Global Product Development
United Animal Health
 

Martijn Adorf

CEO
Animal Health Concepts

Martijn Adorf has a career in life sciences companies in global, regional and executive management roles. Before joining Animal Health Concepts as CEO and shareholder in 2020, he partnered with investors and start-up/scale-up companies acting in the sustainable feed-food value chain. From 2013 until end 2017 he was at Nutreco (part of SHV) as Managing Director of the Business Unit Feed Additives and member of Nutreco’s Executive Committee.

Martijn Adorf

CEO
Animal Health Concepts

Martijn Adorf

CEO
Animal Health Concepts

Martijn Adorf has a career in life sciences companies in global, regional and executive management roles. Before joining Animal Health Concepts as CEO and shareholder in 2020, he partnered with investors and start-up/scale-up companies acting in the sustainable feed-food value chain. From 2013 until end 2017 he was at Nutreco (part of SHV) as Managing Director of the Business Unit Feed Additives and member of Nutreco’s Executive Committee. He led the global growth of the Selko’s feed additives business, focusing on reduction of antibiotics in livestock production, and the acquisition of Micronutrients (USA). From 2005 – 2013 he held various global management roles at Royal DSM, where his focus was on human nutrition ingredients for health. In the 1990s he was in AkzoNobel’s medical diagnostics group and eventually led their regional business in South-East Asia.

He is currently also member of the supervisory board at Vaneeghen, a 360-year-old Dutch food ingredient specialist.

Mr. Adorf holds an MSc in biochemistry from Radboud University Nijmegen, Netherlands.

 

 

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX
 

Matt Dobbs

Global Chief Medical Officer
Destination Pet

Matt Dobbs

Global Chief Medical Officer
Destination Pet

Matt Dobbs

Global Chief Medical Officer
Destination Pet
 

Pete Selover

CEO
Exubrion

Pete Selover

CEO
Exubrion

Pete Selover

CEO
Exubrion
 

Pawel Wielgus

CEO
Bioceltix

Pawel Wielgus

CEO
Bioceltix

Pawel Wielgus

CEO
Bioceltix
 

Deborah Dullen

President and CEO
BioTraceIT

Deborah Dullen

President and CEO
BioTraceIT

Deborah Dullen

President and CEO
BioTraceIT
 

Alain Wille

CEO
Animab

Alain Wille

CEO
Animab

Alain Wille

CEO
Animab
 

Isabelle Delannoy

Phibro Pets
Phibro Animal Health

Isabelle Delannoy

Phibro Pets
Phibro Animal Health

Isabelle Delannoy

Phibro Pets
Phibro Animal Health
 

Andrew Knight

Director
Centre for Animal Welfare, University of Winchester

Andrew Knight

Director
Centre for Animal Welfare, University of Winchester

Andrew Knight

Director
Centre for Animal Welfare, University of Winchester
 

John Howie

CEO
Lintbells

Dr John Howie is CEO & Co-founder of Lintbells, makers of the UK’s number 1 joint supplement, YuMOVE. On a mission to give pets an active life for life, Lintbells has a large share of the UK market and is expanding into the US, European and Asian markets.

John Howie

CEO
Lintbells

John Howie

CEO
Lintbells

Dr John Howie is CEO & Co-founder of Lintbells, makers of the UK’s number 1 joint supplement, YuMOVE. On a mission to give pets an active life for life, Lintbells has a large share of the UK market and is expanding into the US, European and Asian markets.

 

Holly Ganz

Chief Science Officer
Animal Biome

Holly Ganz

Chief Science Officer
Animal Biome

Holly Ganz

Chief Science Officer
Animal Biome
 

Ben Sweeney

Founder
VidiVet

Ben Sweeney

Founder
VidiVet

Ben Sweeney

Founder
VidiVet
 

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan Mackay

Executive Partner and Founder
GHO Capital
 

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

 

Amanda Burkardt

Founder and CEO
Nutripeutics

Amanda Burkardt

Founder and CEO
Nutripeutics

Amanda Burkardt

Founder and CEO
Nutripeutics
 

Lauren Carde

VP Operations and Regulatory Affairs
Paul Dick & Associates Ltd

Lauren Carde

VP Operations and Regulatory Affairs
Paul Dick & Associates Ltd

Lauren Carde

VP Operations and Regulatory Affairs
Paul Dick & Associates Ltd
 

Aleksandra Szopinska

Senior Innovation & Npd Manager
Livalta/AB Agri, UK

Aleksandra Szopinska

Senior Innovation & Npd Manager
Livalta/AB Agri, UK

Aleksandra Szopinska

Senior Innovation & Npd Manager
Livalta/AB Agri, UK
 

Robert Hof

Head of Digital & GSM Excellence
Boehringer Ingelheim

Robert Hof

Head of Digital & GSM Excellence
Boehringer Ingelheim

Robert Hof

Head of Digital & GSM Excellence
Boehringer Ingelheim
 

Gerald Behrens

Global Head of Ruminants
Boehringer Ingelheim

Gerald Behrens

Global Head of Ruminants
Boehringer Ingelheim

Gerald Behrens

Global Head of Ruminants
Boehringer Ingelheim
 

Alan Beynon

Director, Managing Director Poultry Sense
MSD Animal Health

Alan Beynon

Director, Managing Director Poultry Sense
MSD Animal Health

Alan Beynon

Director, Managing Director Poultry Sense
MSD Animal Health
 

Shail Thaker

Senior Partner
McKinsey & Co

Shail Thaker

Senior Partner
McKinsey & Co

Shail Thaker

Senior Partner
McKinsey & Co
 

Peter McCarthy

COO North America
Argenta

Peter McCarthy

COO North America
Argenta

Peter McCarthy

COO North America
Argenta
 

Avner Finger

Global R&D Manager - Vaccine
Phibro

Avner Finger

Global R&D Manager - Vaccine
Phibro

Avner Finger

Global R&D Manager - Vaccine
Phibro
 

Jason Scott

Head of Start-up Development Ecosystem - USA
Google

Jason Scott

Head of Start-up Development Ecosystem - USA
Google

Jason Scott

Head of Start-up Development Ecosystem - USA
Google
 

Heiner Lehr

CEO
Faromatics

Heiner Lehr

CEO
Faromatics

Heiner Lehr

CEO
Faromatics
 

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals Global Animal Health Association

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals Global Animal Health Association

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals Global Animal Health Association

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University

 

Brian Axe

Managing Director
NovaQuest Capital Management

Brian Axe

Managing Director
NovaQuest Capital Management

Brian Axe

Managing Director
NovaQuest Capital Management
 

Michael Hemprich

Director of Strategy and Business Development
Ceva Sante Animale

Dr. Michael Hemprich has almost 20 years experience in the Animal Health Industry and prior to joining IDT-Biologika in March, 2014, he was Manager of Business Development and country Manager for Germany and Austria at Dechra Pharmaceuticals. Prior to joining Dechra, he held senior management positions including Vice President Global Business Development & R&D at LAB International (Montreal, Canada), Regulatory Affairs Manager at Intervet Innovation GmbH and International Technical Manager for Bremer Pharma GmbH.

Michael Hemprich

Director of Strategy and Business Development
Ceva Sante Animale

Michael Hemprich

Director of Strategy and Business Development
Ceva Sante Animale

Dr. Michael Hemprich has almost 20 years experience in the Animal Health Industry and prior to joining IDT-Biologika in March, 2014, he was Manager of Business Development and country Manager for Germany and Austria at Dechra Pharmaceuticals. Prior to joining Dechra, he held senior management positions including Vice President Global Business Development & R&D at LAB International (Montreal, Canada), Regulatory Affairs Manager at Intervet Innovation GmbH and International Technical Manager for Bremer Pharma GmbH.

Michael graduated as veterinary surgeon from the University of Giessen and earned a doctorate degree of Veterinary Medicine from the Ludwig-Maximilians-University Munich. He is also a Member of the Royal College of Veterinary Surgeons and has an executive MBA in Biotechnology.

 

Jamie Brannan

President International Operations
Zoetis

Jamie Brannan

President International Operations
Zoetis

Jamie Brannan

President International Operations
Zoetis
 

Ian Anderson

Director, Allflex UK Lead
MSD Animal Health

Ian Anderson

Director, Allflex UK Lead
MSD Animal Health

Ian Anderson

Director, Allflex UK Lead
MSD Animal Health
 

Fatou Sow

General Manager, Boehringer Ingelheim Veterinary Medicine Belgium
Boehringer Ingelheim

Fatou Sow

General Manager, Boehringer Ingelheim Veterinary Medicine Belgium
Boehringer Ingelheim

Fatou Sow

General Manager, Boehringer Ingelheim Veterinary Medicine Belgium
Boehringer Ingelheim
 

Julia Belaya

Head of International Business Development
Kinship

Julia heads international business development for Kinship, working to accelerate the growth of the Kinship portfolio in the UK, Europe and other key international markets. She drives new customer acquisition and revenue growth for Kinship’s portfolio of businesses by identifying strategic partners, investment opportunities and market gaps.

Julia Belaya

Head of International Business Development
Kinship

Julia Belaya

Head of International Business Development
Kinship

Julia heads international business development for Kinship, working to accelerate the growth of the Kinship portfolio in the UK, Europe and other key international markets. She drives new customer acquisition and revenue growth for Kinship’s portfolio of businesses by identifying strategic partners, investment opportunities and market gaps.

Prior to Kinship, Julia was the Global Head of Business Development at Plug and Play, the world's largest early stage investor, accelerator, and corporate innovation platform. During her time there, Julia grew the Digital Health program to over 20 leading corporate partners  and locations all over the US, Europe, South America and Asia.

 

Kerli Ats

Chief Executive Officer
Estonian Farmers Federation & Member of EESC

Kerli Ats

Chief Executive Officer
Estonian Farmers Federation & Member of EESC

Kerli Ats

Chief Executive Officer
Estonian Farmers Federation & Member of EESC
 

Daniel Baertschi

Food and Agriculture Sector Lead
Quantis

Daniel Baertschi

Food and Agriculture Sector Lead
Quantis

Daniel Baertschi

Food and Agriculture Sector Lead
Quantis
 

Mareese Keane

Co-Founder
Opengate

Mareese Keane

Co-Founder
Opengate

Mareese Keane

Co-Founder
Opengate
 

Theo Kanellos

Director of Business Development & Commercial Alliances
Zoetis

Theo Kanellos is a veterinarian with postgraduate studies in business and life sciences to a PhD level. During his career he worked as a clinician, an academic, a governmental official and for the last fifteen years as part of the management within the Pharmaceutical Industry where he has held several strategic roles.

Theo Kanellos

Director of Business Development & Commercial Alliances
Zoetis

Theo Kanellos

Director of Business Development & Commercial Alliances
Zoetis

Theo Kanellos is a veterinarian with postgraduate studies in business and life sciences to a PhD level. During his career he worked as a clinician, an academic, a governmental official and for the last fifteen years as part of the management within the Pharmaceutical Industry where he has held several strategic roles. He has managed research laboratories, business development transactions, scientific and multi-functional alliances teams and programmes in several organisations that have led to the spinoff of biotechnology companies, the award of significant scientific grants, the founding of major strategic partnerships and the registration and licensing of successful commercial products and services. In his current role as the Director of Commercial Alliances in Zoetis he establishes entrepreneurial partnerships with companies, VCs, universities, and governmental institutions, internationally. He holds a visiting professorship at the School of Health and Medicine at the University of Surrey and is a board member of the Pirbright Institute in UK, the Global Alliance for Livestock Veterinary Medicines (GALVmed) in Africa and head of the action groups of the One Health Platform. He is the author of more than 30 peered reviewed papers and has given numerous presentations in several national and international conferences. His articles have also featured in many trade and public media.

 

Tomas Norton

Professor, Precision Livestock Farming
Ku Leuven

Tomas Norton

Professor, Precision Livestock Farming
Ku Leuven

Tomas Norton

Professor, Precision Livestock Farming
Ku Leuven
 

Joost Matthijssen

Director of Venturing
Nutreco

Joost Matthijssen

Director of Venturing
Nutreco

Joost Matthijssen

Director of Venturing
Nutreco
 

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

 

David Christensen

Dairy and Beef Farmer
Kingston Hill Farm and Aria

David Christensen

Dairy and Beef Farmer
Kingston Hill Farm and Aria

David Christensen

Dairy and Beef Farmer
Kingston Hill Farm and Aria
 

Edward McGruder

Global Head of R&D and Innovation
Argenta

Edward McGruder

Global Head of R&D and Innovation
Argenta

Edward McGruder

Global Head of R&D and Innovation
Argenta
 

Mathews Mmopi

Partner
McKinsey and Company

Mathews Mmopi

Partner
McKinsey and Company

Mathews Mmopi

Partner
McKinsey and Company
 

Aaron Schacht

President/ CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines.

Aaron Schacht

President/ CEO
BIomEdit

Aaron Schacht

President/ CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

 

Jimmy Owens

COO
Axiota Animal Health

Jimmy Owens

COO
Axiota Animal Health

Jimmy Owens

COO
Axiota Animal Health
 

Nicolas Besse

External Development Director
Adisseo

Nicolas Besse

External Development Director
Adisseo

Nicolas Besse

External Development Director
Adisseo
 

Philip Watson

Global Technical Director, Pet Therapeutics
Boehringer Ingelheim

Philip Watson

Global Technical Director, Pet Therapeutics
Boehringer Ingelheim

Philip Watson

Global Technical Director, Pet Therapeutics
Boehringer Ingelheim
 

Maye Walraven

Head of Business Development
InnovaFeed

Maye leads InnovaFeed’s Business Development team, she’s in charge of building value for customers by developing the company’s innovative products. As part of her role, she oversees InnovaFeed’s relationships with various stakeholders across the value chain, from feed manufacturers, to farmers, distributors, NGOs and certification bodies. Prior to joining InnovaFeed she worked at McKinsey & Company as part of the Sustainability and Resource Productivity practice in New York (USA) for 5 years and helped clients deploy sustainable business solutions.

Maye Walraven

Head of Business Development
InnovaFeed

Maye Walraven

Head of Business Development
InnovaFeed

Maye leads InnovaFeed’s Business Development team, she’s in charge of building value for customers by developing the company’s innovative products. As part of her role, she oversees InnovaFeed’s relationships with various stakeholders across the value chain, from feed manufacturers, to farmers, distributors, NGOs and certification bodies. Prior to joining InnovaFeed she worked at McKinsey & Company as part of the Sustainability and Resource Productivity practice in New York (USA) for 5 years and helped clients deploy sustainable business solutions. Maye has a Bachelor of Engineering from Centrale Paris (France) and a master’s in Business Sustainability from the University of Queensland (Australia).

 

Lisa Williams

Director of Business Development
Agri-EPI Centre

Lisa Williams

Director of Business Development
Agri-EPI Centre

Lisa Williams

Director of Business Development
Agri-EPI Centre
 

Chris Howarth

CSO
smaXtec

Chris Howarth

CSO
smaXtec

Chris Howarth

CSO
smaXtec
 

Alasdair Cook

Head
Veterinary Health Innovation Engine (vHive)

Alasdair “Alex” Cook is a veterinary epidemiologist with more than 25 years national and international experience in livestock animal health in Government, academic and development environments. He joined the new School of Veterinary Medicine in January 2013. Previously, he worked in the Animal Health and Veterinary Laboratories Agency (AHVLA) where he was a senior member of staff engaged in leading research and surveillance programmes as well as part of the senior management team formulating strategy and implementing change.

Alasdair Cook

Head
Veterinary Health Innovation Engine (vHive)

Alasdair Cook

Head
Veterinary Health Innovation Engine (vHive)

Alasdair “Alex” Cook is a veterinary epidemiologist with more than 25 years national and international experience in livestock animal health in Government, academic and development environments. He joined the new School of Veterinary Medicine in January 2013. Previously, he worked in the Animal Health and Veterinary Laboratories Agency (AHVLA) where he was a senior member of staff engaged in leading research and surveillance programmes as well as part of the senior management team formulating strategy and implementing change. His interest in epidemiology grew from working in farm animal veterinary practice in the UK and in preventive veterinary medicine. A decade of overseas experience in Yemen, Zambia and Mexico working with poor rural communities underlined the important role that veterinary epidemiology plays in supporting animals in sustainable livelihoods and poverty alleviation. A professional life engaged with and leading multi-disciplinary teams makes Alex a natural proponent of the One Health perspective.

 

Mark Davies

Senior Director, Head of Digital and Multi Channel Marketing (International)

Mark Davies

Senior Director, Head of Digital and Multi Channel Marketing (International)

Mark Davies

Senior Director, Head of Digital and Multi Channel Marketing (International)
 

Mark Boddy

CEO
PawSquad

Mark Boddy

CEO
PawSquad

Mark Boddy

CEO
PawSquad
 

Ian Hamilton

Non-Executive Director
Anpario

Ian Hamilton

Non-Executive Director
Anpario

Ian Hamilton

Non-Executive Director
Anpario
 

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

 

Melanie Munro

Global Lead Regulatory Science Animal Health
Knoell Group

Melanie Munro

Global Lead Regulatory Science Animal Health
Knoell Group

Melanie Munro

Global Lead Regulatory Science Animal Health
Knoell Group
 

Stephen Ainscough

Vice President Information and Technology Services
Zoetis

Stephen Ainscough

Vice President Information and Technology Services
Zoetis

Stephen Ainscough

Vice President Information and Technology Services
Zoetis
 

Emily Stein

CEO
Primal Health

Emily Stein, PhD. Founded Primal Health, LLC in 2017 to focus on improving the dental health of both humans and animals by producing oral microbiome modulation products. She has spent 12 years developing SMMRT technology at Primal Therapies, Inc., which is focused on using metabolic influences to re-engineer disease-causing bacterial biofilms into those that are health-promoting, to decrease inflammation and to improve outcomes.

Emily Stein

CEO
Primal Health

Emily Stein

CEO
Primal Health

Emily Stein, PhD. Founded Primal Health, LLC in 2017 to focus on improving the dental health of both humans and animals by producing oral microbiome modulation products. She has spent 12 years developing SMMRT technology at Primal Therapies, Inc., which is focused on using metabolic influences to re-engineer disease-causing bacterial biofilms into those that are health-promoting, to decrease inflammation and to improve outcomes. Prior to that, she spent 7 years as a research fellow at Stanford University in Rheumatology and Immunology focused on the neuro-endocrine-immune axis in autoimmune and chronic inflammatory diseases. She holds a Phd. in Microbiology from the University of California at Berkeley where she studied inter- and intra-cellular signalling pathways involved in stress response and community development in bacteria and received her B.S. in Microbiology and Immunology at the University of Iowa where she studied the interaction between M. tuberculosis and innate immune cells

 

Jolyon Martin

Founder
PetMedix

Jolyon Martin

Founder
PetMedix

Jolyon Martin

Founder
PetMedix
 

Nuala Summerfield

Director
Virtual Veterinary Specialists

Nuala Summerfield

Director
Virtual Veterinary Specialists

Nuala Summerfield

Director
Virtual Veterinary Specialists
 

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC
 

Patricia Barclay

Founder
Bonaccord Law

Patricia Barclay

Founder
Bonaccord Law

Patricia Barclay

Founder
Bonaccord Law
 

Roman Makovitskiy

Managing Director & Global Head of Animal Health Investment Banking
BofA Securities

Roman Makovitskiy

Managing Director & Global Head of Animal Health Investment Banking
BofA Securities

Roman Makovitskiy

Managing Director & Global Head of Animal Health Investment Banking
BofA Securities
 

Mo Langhi

Senior Business Development Manager
CosmosID

Mo Langhi

Senior Business Development Manager
CosmosID

Mo Langhi

Senior Business Development Manager
CosmosID
 

Kugan Sathiyanandarajah

Managing Director
KKR

Kugan Sathiyanandarajah

Managing Director
KKR

Kugan Sathiyanandarajah

Managing Director
KKR
 

Chris van den Berg

CEO
FarmTrace

Chris van den Berg

CEO
FarmTrace

Chris van den Berg

CEO
FarmTrace
 

Jean-Luc Troch

President
Diagnostics for Animals

Jean-Luc Troch

President
Diagnostics for Animals

Jean-Luc Troch

President
Diagnostics for Animals
 

Dr. Lawrence Brown

Animal Sciences and Aquaculture Sector Specialist
Centre for Innovation Excellence in Livestock (CIEL)

Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.

Dr. Lawrence Brown

Animal Sciences and Aquaculture Sector Specialist
Centre for Innovation Excellence in Livestock (CIEL)

Dr. Lawrence Brown

Animal Sciences and Aquaculture Sector Specialist
Centre for Innovation Excellence in Livestock (CIEL)

Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.

Download the Agenda

Find out who is speaking at Animal Health, Nutrition and Technology Innovation Europe 2022. 

Fill out this short form to download the latest agenda. 

2022 discussions include:

  • Improving animal health through interventions in monoclonal antibodies
  • The opportunities for transgenic and genome editing technologies in the health of production animals
  • How the expectations of Gen-Z and Millennials are transforming technology for companion animals
  • Finding the middle ground between sustainability, economic efficiency, and profitability for all stakeholders across the supply chain
  • How robotics and AI can improve the efficiency and sustainability of livestock farming


Download the Agenda

Advisory Board

Author:

Glenn David

Executive Vice President and Group President, International Operations
Zoetis Inc.

Glenn David

Executive Vice President and Group President, International Operations
Zoetis Inc.

Author:

Aaron Schacht

President/ CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Aaron Schacht

President/ CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Author:

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.

Author:

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Author:

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Author:

Linda Rhodes

Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Linda Rhodes

Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Author:

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

Selection Committee

Author:

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Author:

Matthias Hofer

Managing Partner
Stonehaven Consulting Group

Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.

Matthias Hofer

Managing Partner
Stonehaven Consulting Group

Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.

Author:

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

Author:

Claire Smith

Biotech VC
Anterra Capital

Claire is an Associate at Anterra Capital. Prior to joining Anterra, she was the Chief of Staff at Crestovo, a biotech start-up developing microbiome-based therapies for infectious diseases. Before that, she worked as a consultant at ClearView Healthcare Partners, where she advised pharmaceutical and biotech clients on a variety of growth strategy topics. She graduated from the Massachusetts Institute of Technology with Bachelor of Science degrees in biological engineering and management science.

Claire Smith

Biotech VC
Anterra Capital

Claire is an Associate at Anterra Capital. Prior to joining Anterra, she was the Chief of Staff at Crestovo, a biotech start-up developing microbiome-based therapies for infectious diseases. Before that, she worked as a consultant at ClearView Healthcare Partners, where she advised pharmaceutical and biotech clients on a variety of growth strategy topics. She graduated from the Massachusetts Institute of Technology with Bachelor of Science degrees in biological engineering and management science.

Author:

Cynthia Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Cynthia Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Author:

Dino Dedic, CFA

Senior Managing Director
Guggenheim Partners

Dino Dedic, CFA

Senior Managing Director
Guggenheim Partners

Author:

Paul Dick

President
Paul Dick & Associates Ltd and Managing Partner, Vet Venture Capital Inc.

Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

Paul Dick

President
Paul Dick & Associates Ltd and Managing Partner, Vet Venture Capital Inc.

Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

Author:

Duane Cantrell

Managing Partner
Fulcrum Global Capital




Duane Cantrell

Managing Partner
Fulcrum Global Capital




Author:

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure Partners

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure Partners

Author:

Yorán Meijers

Food Agriculture VC
Anterra Capital

Yorán is an Analyst at Anterra Capital. He is primarily responsible for deal sourcing and execution with a focus on digital technologies. He is also involved in portfolio management.

Prior to joining Anterra, Yorán was active as a researcher in the Creative Machines Lab at Columbia University, focused on developing novel cooking techniques for 3D food printing applications. Before that, he has worked at the process technology department at Heinz and the product and process development department at Cargill.

Yorán holds a MSc in Sustainable Food Process Engineering and a BSc in Food Technology from Wageningen University with a BSc minor in Food Business and Management from UC Davis.

Yorán Meijers

Food Agriculture VC
Anterra Capital

Yorán is an Analyst at Anterra Capital. He is primarily responsible for deal sourcing and execution with a focus on digital technologies. He is also involved in portfolio management.

Prior to joining Anterra, Yorán was active as a researcher in the Creative Machines Lab at Columbia University, focused on developing novel cooking techniques for 3D food printing applications. Before that, he has worked at the process technology department at Heinz and the product and process development department at Cargill.

Yorán holds a MSc in Sustainable Food Process Engineering and a BSc in Food Technology from Wageningen University with a BSc minor in Food Business and Management from UC Davis.

Author:

Benjamin Shaw

Partner
Borealis Ventures

Benjamin Shaw

Partner
Borealis Ventures

Author:

Nicky Deasy

Managing Partner
The Yield Lab Europe

Nicky Deasy

Managing Partner
The Yield Lab Europe

Author:

Barry Brackner

Strategy Consultant Former Marketing & Commercial Director
CVS

Barry is a strategy consultant to the pharma, welfare, retail, tech and veterinary profession having previously held senior executive roles within the veterinary profession most recently an executive board role at CVS as Marketing and Commercial Director, the largest PLC veterinary group in Europe, a role which involved him developing and delivering marketing strategies for the organisation and its member practices and honing its commercial operations. This role saw him supporting growth and the integration of over 300 veterinary practices, crematoria, out of hours clinics and multi-disciplinary hospitals and bringing to market a number of own label prescription and non-prescription products.

Barry Brackner

Strategy Consultant Former Marketing & Commercial Director
CVS

Barry is a strategy consultant to the pharma, welfare, retail, tech and veterinary profession having previously held senior executive roles within the veterinary profession most recently an executive board role at CVS as Marketing and Commercial Director, the largest PLC veterinary group in Europe, a role which involved him developing and delivering marketing strategies for the organisation and its member practices and honing its commercial operations. This role saw him supporting growth and the integration of over 300 veterinary practices, crematoria, out of hours clinics and multi-disciplinary hospitals and bringing to market a number of own label prescription and non-prescription products.

Author:

Sébastien Lafon

Founder
Adapt1st LLC

Sébastien Lafon

Founder
Adapt1st LLC

Author:

Eli Hasson

Founding Partner
PHIL Ventures

Eli Hasson is founding partner of PHIL Ventures (Pet Health Innovation Labs) – the early-stage investments arm of Australia’s PETstock group.

Based in Tel Aviv, Eli has over 25 years’ experience in the Israeli tech sector – with deep knowledge in business strategy and multi-national operations. He was involved in multiple disruptive digital health ventures and led several technology mega-projects. Eli co-founded Quantum Discoveries – an industry-disrupting mineral exploration company that develops and deploys innovative technologies, operating in Chile and US.

Besides his passion for tech & innovation, Eli is an avid jazz musician and improviser.

 

Eli Hasson

Founding Partner
PHIL Ventures

Eli Hasson is founding partner of PHIL Ventures (Pet Health Innovation Labs) – the early-stage investments arm of Australia’s PETstock group.

Based in Tel Aviv, Eli has over 25 years’ experience in the Israeli tech sector – with deep knowledge in business strategy and multi-national operations. He was involved in multiple disruptive digital health ventures and led several technology mega-projects. Eli co-founded Quantum Discoveries – an industry-disrupting mineral exploration company that develops and deploys innovative technologies, operating in Chile and US.

Besides his passion for tech & innovation, Eli is an avid jazz musician and improviser.

 

Author:

Matthieu Vermersch

VVNP's Founder & Managing Partner
VisVires New Protein Capital

Matthieu Vermersch

VVNP's Founder & Managing Partner
VisVires New Protein Capital

2022 Partners

Animal Health Innovation Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.

Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health, Nutrition and Technology Innovation series.

Headline Partner

Associate Partners

Start-Up Development Partner

Knowledge Partner

Consulting Partner

Gold Partners

Media Partners

Become a partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920, email Stephen Swarray at [email protected], Harrison Sharp at [email protected] or downloading our agenda and clicking the "Interested in Sponsorship" box below.

Press Partnerships

Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:

  • Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
  • Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
  • Provide one free press pass to attend
  • Distribute promotional materials at the conference

If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:

Sarah Rowlands
Senior Marketing Manager
T: +44 (0)203 696 2920
E: sarah.rowlands@kisacoresearch.com

Photo Gallery

Remember in-person events? We can't wait to return to face-to-face, until then, check out photos of years gone by. View the full photo gallery here

Venue

etc.venues 133 Houndsditch, Liverpool St, London EC3A 7BX

To see a list of nearby hotels, please click here.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Registration ends in

Monday, February 21, 2022 to Saturday, October 1, 2022
Emerging Companies
£899 + VAT
Pre-Launch Price. Available until the 2023 agenda is released.
Pre-revenue companies
Academics
Charities
Angel and Venture Capital Investors
Please note: Service providers do not qualify for this rate
Monday, February 21, 2022 to Saturday, October 1, 2022
Delegate
£1,899 + VAT
Pre-Launch Price. Available until the 2023 agenda is released.
Animal Health, Nutrition and Tech Companies with under £100m in annual revenue
Pharmaceutical Companies with under £100m in annual revenue
To increase your brand presence, contact Stephen: [email protected]
Monday, February 21, 2022 to Saturday, October 1, 2022
Multinationals and Service Providers
£2,399+VAT
Pre-Launch Price. Available until the 2023 agenda is released.
Animal Health, Nutrition and Tech Companies with over £100m in annual revenue
Pharmaceutical Companies with over £100m in annual revenue
Private Equity Investors & Brokers
Consultants, M&A Advisors
Vet Service Companies
Start-Up Incubators & Accelerators
CROs & CMOs
To increase your brand presence, contact Stephen: [email protected]
Preparing registration...
Payment Terms for Animal Health Investment Europe:
  • Please note that a £49 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us